The Latest Cardiac and Vascular News
April 25, 2024 04:15 PM Eastern Daylight Time IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 […]
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day […]
IRVINE, Calif.–(BUSINESS WIRE)– Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system […]
IRVINE, Calif., July 26, 2023 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2023. Highlights and Outlook Q2 sales grew 11 percent to $1.53 billion; constant currency1 sales grew 12 percent All product groups achieved double digit constant currency […]
In Europe, of the 2.5 million patients undergoing high-risk surgery annually, one in four develops serious postoperative complications.1,2 Intraoperative hypotension (critical drops in blood pressure during surgery) is associated with mortality and major postoperative complications (myocardial injury, acute kidney injury).(3-8) […]
PARIS, May 17, 2023 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) announced today that new data from the Benchmark Registry in Europe demonstrated the safety and effectiveness of this streamlined treatment pathway for patients receiving transcatheter aortic valve replacement (TAVR) with balloon-expandable valves. The data were […]
IRVINE, Calif., April 26, 2023 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2023. Highlights and Outlook Q1 sales grew 9 percent to $1.46 billion; constant currency1 sales grew 13 percent Q1 TAVR sales grew 8 percent; constant […]
Hoag is one of the first three sites in the nation enrolling patients in a post-market study Hoag cardiac surgeons are among an elite class of specialists experienced with this latest generation valve option Study expected to grow to include […]
NEW ORLEANS, March 6, 2023 — Edwards Lifesciences (NYSE: EW) today highlighted new important data examining mortality rates and cardiac damage of early-stage aortic stenosis (AS) sufferers, along with data examining 10-year transcatheter aortic valve replacement (TAVR) re-intervention rates using real-world […]
IRVINE, Calif., Jan. 31, 2023 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2022. Highlights and Outlook Q4 sales grew 1 percent to $1.35 billion; constant currency1 sales grew 7 percent Q4 TAVR sales were flat; constant currency […]
